European Alliance of Associations for Rheumatology Annual Congress (EULAR 2025)

Treatment with bimekizumab showed sustained efficacy for up to 3 years in patients with nonradiographic (nr) and radiographic (r) axial spondyloarthritis (axSpA), based on a pooled analysis of the two phase III studies (BE MOBILE 1 and 2) and combined open-label extension (OLE) study presented at EULAR 2025.

Treatment with inebilizumab reduced the risk of disease flares in patients with immunoglobulin G4-related disease (IgG4-RD) irrespective of sex, age, or race, according to a subgroup analysis of the phase III MITIGATE study presented at EULAR 2025.

Adding the novel CD40L inhibitor dapirolizumab pegol (DZP) to standard of care appears to help patients with systemic lupus erythematosus (SLE) achieve low disease activity and remission, according to a prespecified secondary outcome analysis of the phase III PHOENYCS GO trial.

New research suggests that glucagon-like peptide-1 receptor agonists (GLP-1 RAs), commonly used for diabetes and obesity, may hold therapeutic potential for patients with fibromyalgia.

Treatment with nerandomilast demonstrates efficacy in slowing forced vital capacity (FVC) decline in patients with autoimmune interstitial lung disease (ILD) similar to that seen in the overall trial population, reveals a subgroup analysis of the FIBRONEER-ILD study.

In a post hoc analysis using the phase III REGENCY study dataset, obinutuzumab on top of standard therapy (ST) demonstrates significant superiority to placebo plus ST across numerous renal response definitions in patients with active lupus nephritis (LN).